This figure represents one of the highest weight loss results observed in clinical trials for obesity medications as of 2024, positioning Retatrutide as a potential game-changer in the fight against obesity
Mazdutide Availability Mazdutide received approval in China in 2024 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
Always consult your healthcare provider before making major changes to your dosing schedule or traveling with a large supply of medication
Data analysed by one-way ANOVA, multiple comparison, Bonferroni post hoc test ( e , f , k and l ) and two-way repeated measures ANOVA to assess main effects of treatment ( b , d , h - j , n and p )
The peptide has been studied for optimization of natural GH production patterns (PMID: 9849822), though it has not been extensively studied for age-related hormone decline or adult growth hormone deficiency in clinical trials
If you havent noticed a decrease in appetite after several weeks, or if you have any questions or concerns about your medication, please schedule a follow-up with our providers